2020 BRCA testing in ovarian cancer - germline

Scheme description
Testing for germline BRCA1 and BRCA2 variants in ovarian cancer.
Disorders/Gene target(s)
Ovarian cancer
BRCA1
BRCA2
Clinical cases
Three
Testing/analysis
Sample type
DNA in TE buffer
Techniques
Any molecular testing methods.
Assessment
Submit a clinical report to include:
• Genotyping of results
• Interpretation of the result
• Clerical accuracy
Performance criteria are applied.
Eligibility
All laboratories worldwide
Languages
English ONLY
ISO1743 Accredited EQA
No
EQA timeline
Sample dispatchSeptember 2020
Testing period8 weeks
Assessment resultsFebruary 2020
Final Summary reportApril 2020
Other information
Joint EQA with EMQN, sponsored by AstraZeneca
This EQA assesses the testing of BRCA1 and BRCA2 and the interpretation of results with respect to ovarian cancer.
Fee
£0.00
GenQA code
2020BRCAOVG
« Return to EQA scheme list
Go to top